C78.5 C75.9
Conditions
Interventions
Group 1: The retrospectively studied patients treated by SIRT at the Department of Radiology and Nuclear Medicine at Magdeburg University Hospital received the examinations and therapies according to
Sponsors
Universitätsklinikum Magdeburg
Eligibility
Sex/Gender
All
Age
18 Years to 83 Years
Inclusion criteria
Inclusion criteria: - Patients with hepatocellular carcinoma and cholangiocellular carcinoma - Patients with hepatic metastatic carcinoma - Patients who were evaluated by 99mTc-MAA administration and subsequently received SIRT (sequential unilobar, single-stage bilobar (whole liver treatment), or single-stage unilobar) - Determination of liver function parameters (bilirubin, ALAT, ASAT, GLDH) at the following time points: Before 99mTc-MAA administration, 1-3 days after 99mTc-MAA administration, before SIRT (2-4 weeks after 99mTc-MAA administration) and 4-8 weeks after SIRT.
Exclusion criteria
Exclusion criteria: - Participation in the so-called EXPLOSIVE study - Incomplete recording of liver function parameters or patient data. - The sole absence of liver function parameters 4-8 weeks after SIRT is not an exclusion criterion, as this alone concerns the secondary endpoint.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analysis of liver-specific laboratory parameters before and after intra-arterial application of technetium-99-labeled albumin particles with regard to the occurrence of significant laboratory value changes in preparation for SIRT. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoint is to investigate whether a relevant change in liver-specific laboratory parameters has predictive value for the development of postradioembolic hepatotoxicity in terms of REILD (Radioembolization Induced Liver Disease). | — |
Countries
Germany
Contacts
Public ContactMax Seidensticker
Klinik und Poliklinik für Radiologie LMU Klinikum der Universität München
Outcome results
None listed